Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 80,375,744
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.62
  • Price/Cash Flow 18.15
  • Price/Book 2.58

Options Overview Details

View History
  • Implied Volatility 44.23% (-1.20%)
  • Historical Volatility 27.62%
  • IV Percentile 87%
  • IV Rank 58.84%
  • IV High 56.84% on 04/10/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 2) 19.65 (2.58%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 61
  • Volume Avg (30-Day) 993
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 34,820
  • Open Int (30-Day) 39,143
  • Expected Range 742.66 to 781.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $6.15
  • Number of Estimates 7
  • High Estimate $7.82
  • Low Estimate $4.29
  • Prior Year $6.43
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
727.88 +4.89%
on 03/19/26
788.69 -3.20%
on 03/10/26
+3.59 (+0.47%)
since 03/06/26
3-Month
718.38 +6.27%
on 01/20/26
821.11 -7.02%
on 01/09/26
-37.56 (-4.69%)
since 01/08/26
52-Week
476.49 +60.22%
on 06/05/25
821.11 -7.02%
on 01/09/26
+206.64 (+37.11%)
since 04/08/25

Most Recent Stories

More News
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand...

REGN : 765.10 (+0.64%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 19.92 (+2.15%)
BMRN : 57.23 (+1.80%)
REGN : 765.10 (+0.64%)
MRNA : 51.49 (+2.75%)
BIIB : 176.81 (+0.68%)
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen...

REGN : 765.10 (+0.64%)
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2026 financial and operating results on Wednesday,...

REGN : 765.10 (+0.64%)
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

SAN.FP : 80.590 (+0.10%)
REGN : 765.10 (+0.64%)
SNY : 46.89 (+0.13%)
3 Profitable Stocks We Think Twice About

3 Profitable Stocks We Think Twice About

TOL : 140.85 (+5.83%)
DOCN : 90.80 (+4.86%)
REGN : 765.10 (+0.64%)
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Society for Science (the Society) announced that Connor Hill , 17, of State...

REGN : 765.10 (+0.64%)
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09,...

REGN : 765.10 (+0.64%)
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

AAPL : 258.19 (+1.85%)
TXN : 207.61 (+3.94%)
REGN : 765.10 (+0.64%)
Regeneron Announces Investor Conference Presentation

TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at...

REGN : 765.10 (+0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 779.68
2nd Resistance Point 770.80
1st Resistance Point 765.53
Last Price 765.10
1st Support Level 751.38
2nd Support Level 742.50
3rd Support Level 737.23

See More

52-Week High 821.11
Last Price 765.10
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.